Bionix® Launches the Next Generation of Lighted Ear Curettes™ with ClearLook™ Lighted Ear Curette Hitting the Market Today

For nearly 20 years, Bionix has supplied the healthcare industry with its innovative and dependable Lighted Ear Curettes, designed to illuminate and improve visualization of the ear canal for efficient and safe cerumen Removal.

Today, the next generation hits the market with the ClearLook Lighted Ear Curette. Bionix developed this generation by using valuable insight and feedback from medical professionals who regularly used the previous model of Lighted Ear Curettes.

ClearLook Lighted Ear Curettes offer a unique and ergonomic handle design that promotes a natural and comfortable grip out of the line of sight, giving healthcare professionals better control and confidence while performing cerumen removal. ClearLook’s design includes reference markers for re-entry into the ear, improving practitioner and patient satisfaction.

Currently available in the popular FlexLoop® and VersaLoop® tip styles, ClearLook continues to employ illumination and magnification the same as the original Lighted Ear Curettes, but with a less obstructed, more accurate view of the ear canal.

“Bionix is pleased to offer healthcare practitioners this evolved version of our Lighted Ear Curettes that enhances the safety and time of cerumen removal procedures,” states Chris Becker, President and CEO, Bionix, LLC. “We greatly appreciate the ongoing feedback received from practitioners and clinicians as it allows our engineers to enrich our products and ensure that we continue to meet their needs.”

Bionix is committed to working with healthcare professionals to identify opportunities for innovation that enable advances in product development and deploy solutions that address challenges they encounter in patient care.

For a limited time, the new, just-released ClearLook Lighted Ear Curette are the same price as the current FlexLoop and VersaLoop Lighted Ear Curettes. Order now to take advantage of this introductory offer! The special offer expires December 31, 2022.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version